Immuno-cell Therapy
10.1625/jcam.1.85
- VernacularTitle:免疫細胞療法
- Author:
Shigenori GOTO
;
Toru KANEKO
;
Kohji EGAWA
- Publication Type:Journal Article
- Keywords:
Evidence;
randomized control trials (RCT);
immuno-cell therapy;
adoptive immunotherapy;
T lymphocyte;
dendritic cell;
cancer;
response rate;
survival rate
- From:Japanese Journal of Complementary and Alternative Medicine
2004;1(1):85-93
- CountryJapan
- Language:Japanese
-
Abstract:
The growing knowledge of cancer immunology during the past 20 years has led to the current implementation of immunotherapy. Immuno-cell therapy, in which ex vivo processed T lymphocytes and dendritic cells are used as agents, has developed and spread and is now accepted as a common treatment with the identification of a number of cancer peptide antigens. The response rate to immuno-cell therapy is reported to be around 10-20%. Some clinical studies have reported that immuno-cell therapy as a postoperative adjuvant therapy improved survival rates. This paper outlines the historic background and the current medical scene of immuno-cell therapy.
